EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity

Daniel Westaby, Juan M Jiménez-Vacas, Ines Figueiredo, Jan Rekowski, Claire Pettinger, Bora Gurel, Arian Lundberg, Denisa Bogdan, Lorenzo Buroni, Antje Neeb, Ana Padilha, Joe Taylor und 29 weitere

Journal of Clinical Investigation · 17.09.2024 · 134 (18)

DOI: 10.1172/jci179998 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 17.09.2024. Verfasst von Daniel Westaby und 40 weiteren Autor:innen. Beteiligte Einrichtung: The Institute of Cancer Research, London, United Kingdom. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-bcl-2, Prostatic Neoplasms, Castration-Resistant, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Wellcome Trust, Prostate Cancer UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence of AR-independent castration-resistant prostate cancer (CRPC), typically driven by loss of AR expression, lineage plasticity, and transformation to prostate cancers (PCs) that exhibit phenotypes of neuroendocrine or basal-like cells. The anti-apoptotic protein BCL2 is upregulated in neuroendocrine cancers and may be a therapeutic target for this aggressive PC disease subset. There is an unmet clinical need, therefore, to clinically characterize BCL2 expression in metastatic CRPC (mCRPC), determine its association with AR expression, uncover its mechanisms of regulation, and evaluate BCL2 as a therapeutic target and/or biomarker with clinical utility. Here, using multiple PC biopsy cohorts and models, we demonstrate that BCL2 expression is enriched in AR-negative mCRPC, associating with shorter overall survival and resistance to ARSIs. Moreover, high BCL2 expression associates with lineage plasticity features and neuroendocrine marker positivity. We provide evidence that BCL2 expression is regulated by DNA methylation, associated with epithelial-mesenchymal transition, and increased by the neuronal transcription factor ASCL1. Finally, BCL2 inhibition had antitumor activity in some, but not all, BCL2-positive PC models, highlighting the need for combination strategies to enhance tumor cell apoptosis and enrich response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-bcl-2Prostatic Neoplasms, Castration-ResistantGene Expression Regulation, NeoplasticMaleHumansAnimalsCell Line, TumorReceptors, AndrogenMiceDNA MethylationEpithelial-Mesenchymal TransitionBasic Helix-Loop-Helix ProteinsCell LineageNeoplasm Proteins

Stichwörter der Autor:innen

ApoptosisOncologyProstate cancer

Substanzen

Proto-Oncogene Proteins c-bcl-2Receptors, AndrogenBasic Helix-Loop-Helix ProteinsNeoplasm ProteinsBCL2 protein, humanAR protein, human

Autor:innen und Institutionen

  • The Institute of Cancer Research, London, United Kingdom.
  • The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
  • Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Australian Prostate Cancer Research Centre-Queensland, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.
  • University of Washington, Seattle, Washington, USA.

Förderung

  • NCI NIH HHS
  • Wellcome Trust
  • Prostate Cancer UK
  • Medical Research Council
  • Movember Foundation
  • Movember Foundation Australia Leverage Fund
  • the Wellcome Trust
  • Cancer Research UK

Zitieren

APA

Westaby, D., Jiménez-Vacas, J. M., Figueiredo, I., Rekowski, J., Pettinger, C., Gurel, B., Lundberg, A., Bogdan, D., Buroni, L., Neeb, A., Padilha, A., Taylor, J., Zeng, W., Das, S., Hobern, E., Riisnaes, R., Crespo, M., Miranda, S., Ferreira, A., …, & Sharp, A. (2024). BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity. Journal of Clinical Investigation, 134(18). https://doi.org/10.1172/jci179998

Vancouver

Westaby D, Jiménez-Vacas JM, Figueiredo I, Rekowski J, Pettinger C, Gurel B, et al. BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity. Journal of Clinical Investigation. 2024;134(18). doi:10.1172/jci179998

BibTeX
@article{Westaby2024,
  author = {Westaby, Daniel and Jiménez-Vacas, Juan M and Figueiredo, Ines and Rekowski, Jan and Pettinger, Claire and Gurel, Bora and Lundberg, Arian and Bogdan, Denisa and Buroni, Lorenzo and Neeb, Antje and Padilha, Ana and Taylor, Joe and Zeng, Wanting and Das, Souvik and Hobern, Emily and Riisnaes, Ruth and Crespo, Mateus and Miranda, Susana and Ferreira, Ana and Hanratty, Brian P and Nava Rodrigues, Daniel and Bertan, Claudia and Seed, George and Fenor de La Maza, Maria de Los Dolores and Guo, Christina and Carmichael, Juliet and Grochot, Rafael and Chandran, Khobe and Stavridi, Anastasia and Varkaris, Andreas and Stylianou, Nataly and Hollier, Brett G and Tunariu, Nina and Balk, Steven P and Carreira, Suzanne and Yuan, Wei and Nelson, Peter S and Corey, Eva and Haffner, Michael and de Bono, Johann and Sharp, Adam},
  title = {BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {18},
  doi = {10.1172/jci179998}
}
Kostenlos starten →